Evidence map›Paper›PMID 40042752›Full record

ArticleJournal of behavioral medicine2025

Worry about prostate cancer and risk perception among middle-aged men: results from the PROBASE trial.

Valentin H Meissner, Andreas Dinkel, Martina Kron, Stefan Schiele, Matthias Jahnen, Jale Lakes, Jan Philipp Radtke, Markus A Kuczyk, Nina N Harke, Jürgen Debus and 15 more

Abstract read
In one paragraph

Article in Journal of behavioral medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors.

Valentin H MeissnerDepartment of Urology, Klinikum rechts der Isar, School of Medicine and Health, Technical University of Munich, Ismaninger Str. 22, 81675, Munich, Germany. valentin.meissner@tum.de.ORCID 0000-0001-7679-3658
Andreas DinkelDepartment of Psychosomatic Medicine and Psychotherapy, Klinikum rechts der Isar, School of Medicine and Health, Technical University of Munich, Munich, Germany.
Martina KronInstitute of Epidemiology and Medical Biometrics, University of Ulm, Ulm, Germany.
Stefan SchieleDepartment of Urology, Klinikum rechts der Isar, School of Medicine and Health, Technical University of Munich, Ismaninger Str. 22, 81675, Munich, Germany.
Matthias JahnenDepartment of Urology, Klinikum rechts der Isar, School of Medicine and Health, Technical University of Munich, Ismaninger Str. 22, 81675, Munich, Germany.
Jale LakesDepartment of Urology, University Hospital, Medical Faculty, Heinrich-Heine University Duesseldorf, Duesseldorf, Germany.
Jan Philipp RadtkeDepartment of Urology, University Hospital, Medical Faculty, Heinrich-Heine University Duesseldorf, Duesseldorf, Germany.
Markus A KuczykDepartment of Urology, Hannover Medical School, Hannover, Germany.
Nina N HarkeDepartment of Urology, Hannover Medical School, Hannover, Germany.
Jürgen DebusDepartment of Radiation Oncology, Heidelberg University Hospital, Ruprecht Karls University Heidelberg, Heidelberg, Germany.
Christoph A FinkDepartment of Radiation Oncology, Heidelberg University Hospital, Ruprecht Karls University Heidelberg, Heidelberg, Germany.
Gerald AntochDepartment of Diagnostic and Interventional Radiology, Medical Faculty, Duesseldorf, Heinrich-Heine University Duesseldorf, Duesseldorf, Germany.
Lars SchimmöllerDepartment of Diagnostic and Interventional Radiology, Medical Faculty, Duesseldorf, Heinrich-Heine University Duesseldorf, Duesseldorf, Germany.
Glen KristiansenInstitute of Pathology, University Hospital Bonn, Bonn, Germany.
Agne KrilaviciuteDivision of Personalized Early Detection of Prostate Cancer, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Petra SeiboldDivision of Personalized Early Detection of Prostate Cancer, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Sabine BehrensDivision of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Axel BennerDivision of Biostatistics, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Christian ArsovDepartment of Urology, University Hospital, Medical Faculty, Heinrich-Heine University Duesseldorf, Duesseldorf, Germany.
Boris HadaschikDepartment of Urology, University of Duisburg-Essen and German Cancer Consortium (dktk), University Hospital Essen, Essen, Germany.
Nikolaus BeckerDivision of Personalized Early Detection of Prostate Cancer, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Rudolf KaaksDivision of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Peter AlbersDepartment of Urology, University Hospital, Medical Faculty, Heinrich-Heine University Duesseldorf, Duesseldorf, Germany.
Jürgen E GschwendDepartment of Urology, Klinikum rechts der Isar, School of Medicine and Health, Technical University of Munich, Ismaninger Str. 22, 81675, Munich, Germany.
Kathleen HerkommerDepartment of Urology, Klinikum rechts der Isar, School of Medicine and Health, Technical University of Munich, Ismaninger Str. 22, 81675, Munich, Germany.

Funding

Deutsche Krebshilfe 70114830
6 · The paper itself

Abstract

Cancer worry and risk perception are relevant psychological factors that influence preventive health behaviors. Therefore, a thorough understanding of the factors that impact their occurrence and manifestation is critical. The objective of this study was to assess prevalence and factors associated with worry about prostate cancer (PCa) and absolute/comparative risk perception in a community-based sample of 45-year-old men. Data were collected within the German PCa screening trial PROBASE. Variables were assessed by self-report questionnaires and a clinical interview. Worry about PCa and absolute/comparative risk perception were assessed each on a 5-point-Likert scale. Multivariable logistic regression was used to identify factors associated with the outcomes of interest. Data were available for 33,476 (72.0%) of 46,495 men at enrollment. 7.3% had sometimes/(very) often worry about PCa. 3.7% and 9.9% perceived their absolute risk and comparative risk as somewhat high/very high and somewhat higher/much higher, respectively. 18.8% reported a positive PCa family history. Important factors of worry about PCa, absolute risk perception, and comparative risk perception were lower urinary tract symptoms (LUTS) (OR 3.00, 95% CI 2.63-3.42; OR 2.09, CI 1.71-2.56; OR 2.41, CI 2.10-2.76) and a positive PCa family history (OR 2.35, CI 2.08-2.65; OR 15.13, CI 12.73-17.97; OR 9.69, CI 8.76-10.72). A positive history of urological (OR 3.85, CI 2.63-5.63) and non-urological cancers (OR 1.97, CI 1.52-2.54) were associated with a higher comparative risk perception. In conclusion, worry about PCa and risk perception are influenced by non-cancer-related symptoms as well as by a positive PCa family history. These findings need to be addressed in risk communication with patients.

Indexed as

AnxietyHealth Knowledge, Attitudes, PracticeProstatic NeoplasmsGermanyHumansMaleMiddle AgedPerceptionSurveys and QuestionnairesAbsolute risk perceptionCancer worryComparative risk perceptionFamily historyLower urinary tract symptomsProstate cancer

Identifiers

PMID40042752
PMCPMC12078363

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.